Quick Answer
BetterLife Pharma Inc. reported Net Income of -$9.15 million for fiscal year 2019.
BetterLife Pharma Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | — | — | — | — | — | — |
| Diluted EPS | — | — | — | — | — | — |
| Total Assets | $225.0K -30.7% |
$324.7K +334.6% |
$74.7K -93.6% |
$1.16M -13.1% |
$1.34M | — |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | — | — | — | — | — | — |
| R&D Expense | $424.3K -25.7% |
$570.9K -78.7% |
$2.68M -50.6% |
$5.42M +1804.0% |
$284.7K +346.5% |
$63.8K -85.2% |
| Operating Income | — | — | — | — | — | — |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | April 30, 2019 | -$1.87M | +11.0% | +44.5% |
| Diluted EPS | April 30, 2019 | -$0.02 | +33.3% | +50.0% |
| Total Assets | April 30, 2019 | $9.55M | +8.3% | +11.1% |
| Cash and Equivalents | April 30, 2019 | $45.4K | -97.6% | -39.3% |
| Stockholders Equity | April 30, 2019 | $3.37M | -26.7% | -4.0% |
| R&D Expense | April 30, 2019 | $59.5K | -45.3% | -8.5% |
| Operating Income | April 30, 2019 | -$1.66M | +11.5% | -17.7% |
| Shares Outstanding | April 30, 2019 | 105.94M | +20.3% | +9.3% |
- BetterLife Pharma Inc. reported Net Income of -$9.15 million for fiscal year 2019.
- BetterLife Pharma Inc. showed a decrease of -21495.1% in Net Income compared to the prior fiscal year.
- BetterLife Pharma Inc. reported Diluted EPS of $0.11 per share (loss) for fiscal year 2016.
- BetterLife Pharma Inc. showed a decrease of -10.0% in Diluted EPS compared to the prior fiscal year.
- BetterLife Pharma Inc. reported Total Assets of $225.0 thousand for fiscal year 2025.
- BetterLife Pharma Inc. showed a decrease of -30.7% in Total Assets compared to the prior fiscal year.
- BetterLife Pharma Inc. reported Cash and Equivalents of $74.8 thousand for fiscal year 2019.
- BetterLife Pharma Inc. showed a decrease of -5.7% in Cash and Equivalents compared to the prior fiscal year.
- BetterLife Pharma Inc. reported Stockholders Equity of $3.51 million for fiscal year 2019.
- BetterLife Pharma Inc. showed an increase of +6390.6% in Stockholders Equity compared to the prior fiscal year.
- BetterLife Pharma Inc. reported R&D Expense of $424.3 thousand for fiscal year 2025.
- BetterLife Pharma Inc. showed a decrease of -25.7% in R&D Expense compared to the prior fiscal year.
- BetterLife Pharma Inc. reported Operating Income of -$6.84 million for fiscal year 2019.
- BetterLife Pharma Inc. showed a decrease of -405.1% in Operating Income compared to the prior fiscal year.
- BetterLife Pharma Inc. reported Shares Outstanding of 96.90 million shares for fiscal year 2019.
- BetterLife Pharma Inc. showed an increase of +17.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: